Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN KEMPERS

NPI
1003852427
CMS profile
237
Location
FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$8,088.76

14 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,408.00 1
Travel and Lodging $1,179.11 6
Food and Beverage $501.65 7

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $7,838.76 12
Janssen Biotech, Inc. $250.00 2

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN KEMPERS

NPI 1003852427 · CMS profile ID 237

FRIDLEY, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003852427?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003852427?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003852427?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STEVEN KEMPERS, NPI 1003852427, CMS profile ID 237, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1003852427?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

14 matching records · $8,088.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 14 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–14 of 14.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $6,408.0011/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917796 CMS
E.R. Squibb & Sons, L.L.C. $37.2411/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917789 CMS
E.R. Squibb & Sons, L.L.C. $132.0911/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917851 CMS
E.R. Squibb & Sons, L.L.C. $25.1911/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917859 CMS
E.R. Squibb & Sons, L.L.C. $20.5011/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917867 CMS
E.R. Squibb & Sons, L.L.C. $475.7411/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917875 CMS
E.R. Squibb & Sons, L.L.C. $108.9811/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917891 CMS
E.R. Squibb & Sons, L.L.C. $157.5511/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917899 CMS
E.R. Squibb & Sons, L.L.C. $199.0111/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917907 CMS
E.R. Squibb & Sons, L.L.C. $41.0411/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061065497 CMS
E.R. Squibb & Sons, L.L.C. $32.8311/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061065499 CMS
E.R. Squibb & Sons, L.L.C. $200.5911/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014917883 CMS
Janssen Biotech, Inc. $125.0003/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080723609 CMS
Janssen Biotech, Inc. $125.0003/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080723611 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $487.41 9
PY2020 $2,100.00 1
PY2021 $45.00 1
PY2022 $197.59 3
PY2023 $8,088.76 14
PY2024 $2,182.90 6
PY2025 $2,500.00 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $625,552.01 94
PY2024 Principal investigator $714,642.60 239
PY2023 Principal investigator $556,939.59 143
PY2022 Recipient $155.00 1
PY2022 Principal investigator $633,017.42 68
PY2021 Recipient $29,455.27 2
PY2021 Principal investigator $881,507.91 62
PY2020 Principal investigator $539,612.47 58
PY2019 Recipient $15,973.75 2
PY2019 Principal investigator $1,131,652.54 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

239 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,937.36 12/31/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M19-044 Rinvoq Phase 3 Vitiligo No dispute reported 06/30/2026 1100764885
Principal investigator 1 ABBVIE INC. $2,803.90 12/31/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
M23-716 Rinvoq Ph 3 Alopecia Areata No dispute reported 06/30/2026 1100766969
Principal investigator 1 ABBVIE INC. $11,182.50 12/30/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100762982
Principal investigator 1 Janssen Research & Development, LLC $3,059.00 12/23/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002550
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,555.00 12/18/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125501068
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,651.13 12/13/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125500636
Principal investigator 1 ABBVIE INC. $13,256.25 12/05/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100758965
Principal investigator 1 Janssen Research & Development, LLC $12,655.00 12/02/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002546
Principal investigator 1 ABBVIE INC. $527.57 11/21/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1100756025
Principal investigator 1 ABBVIE INC. $8,940.00 11/07/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects With Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1100753287
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,123.12 11/06/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125499194
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 11/01/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 1125498957
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $559.42 10/31/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793374
Principal investigator 1 ABBVIE INC. $3,891.96 10/29/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100750674
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,000.00 10/28/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031078
Principal investigator 1 Janssen Research & Development, LLC $5,739.00 10/28/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002520
Principal investigator 1 Janssen Research & Development, LLC $4,524.00 10/28/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002526
Principal investigator 1 Arcutis Biotherapeutics, Inc. $5,650.00 10/21/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031076
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $758.25 10/17/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793372
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $19,680.75 10/11/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793370
Principal investigator 1 ABBVIE INC. $12,540.00 10/03/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100745658
Principal investigator 1 ABBVIE INC. $5,866.72 10/01/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100744956
Principal investigator 1 Arcutis Biotherapeutics, Inc. $13,029.13 10/01/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031080
Principal investigator 1 Janssen Research & Development, LLC $2,193.00 09/30/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002536
Principal investigator 1 Janssen Research & Development, LLC $7,151.00 09/27/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002532
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,001.25 09/23/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793368
Principal investigator 1 ABBVIE INC. $5,785.00 09/17/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1100742538
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,108.17 09/11/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125497317
Principal investigator 1 ABBVIE INC. $31,702.50 09/04/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100740062
Principal investigator 1 Janssen Research & Development, LLC $4,930.00 08/26/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002548
Principal investigator 1 Janssen Research & Development, LLC $6,585.00 08/22/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002542
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896676
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896680
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896684
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896688
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896692
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896696
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896701
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896705
Principal investigator 1 Dermavant Sciences, Inc. $146.78 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896709
Principal investigator 1 Dermavant Sciences, Inc. $146.78 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896713
Principal investigator 1 Dermavant Sciences, Inc. $105.51 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896722
Principal investigator 1 Dermavant Sciences, Inc. $105.51 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896726
Principal investigator 1 Dermavant Sciences, Inc. $105.51 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896730
Principal investigator 1 Dermavant Sciences, Inc. $105.51 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896735
Principal investigator 1 Dermavant Sciences, Inc. $129.88 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896739
Principal investigator 1 Dermavant Sciences, Inc. $129.88 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896743
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896747
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896751
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896755
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896760
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896768
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896772
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896777
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896781
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896785
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896789
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896793
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896798
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896802
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896806
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896815
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896819
Principal investigator 1 Dermavant Sciences, Inc. $114.42 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896823
Principal investigator 1 Dermavant Sciences, Inc. $114.42 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896828
Principal investigator 1 Dermavant Sciences, Inc. $114.42 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896832
Principal investigator 1 Dermavant Sciences, Inc. $114.42 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896836
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896840
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896844
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896848
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896852
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896860
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896864
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896868
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896873
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896877
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896881
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896885
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896889
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896893
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896897
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896906
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127896910
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900117
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900122
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900126
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900131
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900135
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900139
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900144
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900148
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900156
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900160
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900165
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900169
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900173
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900178
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900182
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900186
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900191
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900195
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900208
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900212
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900216
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900220
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900225
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900229
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127900233
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922123
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922128
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922132
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922136
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922140
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922145
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922149
Principal investigator 1 Dermavant Sciences, Inc. $24.50 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922153
Principal investigator 1 Dermavant Sciences, Inc. $146.78 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922158
Principal investigator 1 Dermavant Sciences, Inc. $146.78 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922162
Principal investigator 1 Dermavant Sciences, Inc. $105.51 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922170
Principal investigator 1 Dermavant Sciences, Inc. $105.51 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922174
Principal investigator 1 Dermavant Sciences, Inc. $105.51 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922178
Principal investigator 1 Dermavant Sciences, Inc. $105.51 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922182
Principal investigator 1 Dermavant Sciences, Inc. $129.88 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922187
Principal investigator 1 Dermavant Sciences, Inc. $129.88 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922191
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922195
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922200
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922204
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922208
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922217
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922221
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922225
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922230
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922234
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922238
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922243
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922247
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922251
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922256
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922264
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922268
Principal investigator 1 Dermavant Sciences, Inc. $114.42 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922272
Principal investigator 1 Dermavant Sciences, Inc. $114.42 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922276
Principal investigator 1 Dermavant Sciences, Inc. $114.42 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922280
Principal investigator 1 Dermavant Sciences, Inc. $114.42 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922285
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922289
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922293
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922297
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922302
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922310
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922314
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922319
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922323
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922327
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922331
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922336
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922340
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922344
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922348
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922357
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127922361
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925575
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925580
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925584
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925588
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925592
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925597
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925601
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925605
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925614
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925618
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925622
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925627
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925631
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925635
Principal investigator 1 Dermavant Sciences, Inc. $132.89 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925639
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925643
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925648
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925652
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925665
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925669
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925673
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925678
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925682
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925686
Principal investigator 1 Dermavant Sciences, Inc. $109.18 08/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127925690
Principal investigator 1 ABBVIE INC. $25,507.50 08/02/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100733938
Principal investigator 1 Janssen Research & Development, LLC $11,266.00 08/01/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002562
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,387.76 08/01/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125494839
Principal investigator 1 Janssen Research & Development, LLC $4,593.00 07/29/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002516
Principal investigator 1 Dermavant Sciences, Inc. $1,300.00 07/23/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879412
Principal investigator 1 Dermavant Sciences, Inc. $5,000.00 07/23/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1127879416
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $18,382.50 07/22/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793366
Principal investigator 1 Incyte Corporation $5,216.85 07/11/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134703663
Principal investigator 1 ABBVIE INC. $19,087.50 07/05/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100727062
Principal investigator 1 Janssen Research & Development, LLC $6,629.00 07/01/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002518
Principal investigator 1 Janssen Research & Development, LLC $11,949.00 07/01/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002528
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,061.50 06/26/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125492976
Principal investigator 1 Janssen Research & Development, LLC $1,138.00 06/20/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002530
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,181.02 06/07/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125492544
Principal investigator 1 ABBVIE INC. $29,302.50 06/06/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100722628
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,073.20 06/06/2024 Non-covered Recipient Entity
Minnesota Clinical Study
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1123478479
Principal investigator 1 Incyte Corporation $6,750.00 06/04/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1134703661
Principal investigator 1 Janssen Research & Development, LLC $12,351.00 06/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002540
Principal investigator 1 Janssen Research & Development, LLC $9,716.00 05/27/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002514
Principal investigator 1 Janssen Research & Development, LLC $2,276.00 05/20/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002544
Principal investigator 1 Amgen Inc. $1,317.00 05/17/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA D/B/A MINNESOTA CLINICAL STUDY CENTER
Ph2 DAX Discoid Lupus DLE OLE No dispute reported 06/30/2026 1096314507
Principal investigator 1 Janssen Research & Development, LLC $1,138.00 05/16/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002556
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 05/10/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125490954
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $412.30 05/10/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125490984
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,155.00 05/10/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125491030
Principal investigator 1 ABBVIE INC. $3,442.50 05/09/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100717146
Principal investigator 1 Amgen Inc. $154.98 05/02/2024 Non-covered Recipient Entity
MINNESOTA CLINICLSTUDYCENTR
Ph2 DAX Discoid Lupus DLE OLE No dispute reported 06/30/2026 1096314537
Principal investigator 1 Janssen Research & Development, LLC $9,817.00 04/29/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002522
Principal investigator 1 Janssen Research & Development, LLC $5,601.00 04/29/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002524
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,959.35 04/19/2024 Non-covered Recipient Entity
Associated Skin Care Specialists
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1123476014
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,181.52 04/19/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALIS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125489991
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $17,707.50 04/17/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793364
Principal investigator 1 ABBVIE INC. $5,004.00 04/11/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 1100713636
Principal investigator 1 Amgen Inc. $230.94 04/09/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
P2 Moderate-Severe pDLE No dispute reported 06/30/2026 1096312677
Principal investigator 1 Amgen Inc. $69.65 04/02/2024 Non-covered Recipient Entity
MINNESOTA CLINICLSTUDYCENTR
Ph2 DAX Discoid Lupus DLE OLE No dispute reported 06/30/2026 1096314539
Principal investigator 1 Acrotech Biopharma Inc. $8,042.89 03/28/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-302 No dispute reported 06/30/2026 1147107922
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,277.80 03/27/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1155196591
Principal investigator 1 Janssen Research & Development, LLC $24,267.00 03/25/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002552
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,048.82 03/20/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA DBA MINNESOTA CLINICAL STUDY CENTER
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1125488383
Principal investigator 1 Janssen Research & Development, LLC $22,194.00 03/18/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002554
Principal investigator 1 Incyte Corporation $5,773.08 03/06/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus No dispute reported 06/30/2026 1134703659
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,385.20 02/27/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
A Phase 3B/4, Multicenter, Randomized, Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Moderate-to-severe Scalp Psoriasis (PSORIATYK SCALP) No dispute reported 06/30/2026 1155196589
Principal investigator 1 Janssen Research & Development, LLC $6,890.00 02/22/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002558
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,456.00 02/07/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1151793376
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,309.99 02/05/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031074
Principal investigator 1 ABBVIE INC. $10,000.00 02/02/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1100702644
Principal investigator 1 Janssen Research & Development, LLC $5,381.00 01/29/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1079002538
Principal investigator 1 Janssen Research & Development, LLC $37,224.00 01/29/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002560
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $207.76 01/25/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUTING THE EFFICACY AND SAFETY OF DEUCRAVACITINIB IN PATIENTS WITH MODERATE TO SEVERE SCALP PSORIASIS No dispute reported 06/30/2026 1123478483
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $26,027.33 01/24/2024 Non-covered Recipient Entity
Minnesota Clinical Study Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1151793362
Principal investigator 1 Janssen Research & Development, LLC $14,820.00 01/18/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1079002534
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,971.64 01/16/2024 Non-covered Recipient Entity
Minnesota Clinical Study Associates
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 1123478481
Principal investigator 1 Acrotech Biopharma Inc. $1,330.20 01/11/2024 Non-covered Recipient Entity
MINNESOTA CLINICAL STUDY CENTER
246-13651-301 No dispute reported 06/30/2026 1147107680
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,499.12 01/03/2024 Non-covered Recipient Entity
ASSOCIATED SKIN CARE SPECIALISTS PA
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031072